You are here: Industry Insights > psilocybin

News List

Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia AmericanPharmaceuticalReview
December 03, 2021
Tryp Therapeutics has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") application is complete and that the Company may proceed with its clinical study in fibromyalgia.
NEWS Depression drug shows positive results in groundbreaking Phase IIb study EuropeanPharmaceuticalReview
November 11, 2021
COMPASS Pathways has announced that its groundbreaking Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression has achieved its primary endpoint...
Silo Pharma Enters Joint Venture with Zylo Therapeutics contractpharma
April 29, 2021
Silo Pharma Inc. a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has entered into a Joint Venture with Zylo Therapeutics.
Magic mushroom compound psilocybin shows ‘promise’ in depression pharmatimes
April 16, 2021
A new study has found that psilocybin, the active compound found in magic mushrooms, could be at least as effective as a leading antidepressant medication in people with moderate-to-severe depression.
Revive Therapeutics partners with Complete Phytochemical Solutions to advance research initiatives for psilocybin-based pharmaceutical products pharmaceutical-business-review
April 22, 2020
Revive Therapeutics has engaged Complete Phytochemical Solutions, which specialises in unique and complex analyses and formulation development of phytochemicals.
COMPASS Granted Patent of Psilocybin Formulation for Treatment-Resistant Depression americanpharmaceuticalreview
January 17, 2020
COMPASS Pathways has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office (USPTO).
Psilocybin study shows positive results in healthy volunteers europeanpharmaceuticalreview
December 16, 2019
In a new study, COMP360 (psilocybin) was well tolerated in healthy volunteers which support further investigation of a simultaneous 1:1 therapeutic administration design.